RISK ASSESSMENT AND MONITORING OF HEPATOTOXIC REACTIONS IN TUBERCULOSIS PATIENTS
https://doi.org/10.21292/2075-1230-2017-95-9-40-48
Abstract
In order to detect risk groups for drug-induced liver lesions and to develop the procedure for differential monitoring of liver tests during tuberculosis chemotherapy, a prospective study was performed including 435 new tuberculosis patients. The one-dimensional and regression analysis helped to identify risk factors of drug-induced liver lesions (female sex, poor nutrition, absentation from smoking, history of medicamentous allergy), and based on them scores for risk assessment before the start of chemotherapy were worked out and validated. Drug-induced liver lesions developed in 110 patients (25.3%, 95% CI 21.4-29.6), of them 45 (40.9%) developed liver lesion during first 14 days after the start of chemotherapy. The group facing a higher risk of drug-induced liver lesions developed them after a longer period of time; the number of early liver lesions made 18.5% in the high-risk group, and 6.6% (p = 0.02) in the low-risk group. The procedure of laboratory monitoring depending on the degree of risk was offered for early diagnostics of drug-induced liver lesions.
About the Authors
D. A. IVАNOVА
Moscow Municipal Scientific Practical Center of Tuberculosis Control
Russian Federation
Russian Federation
Researcher of Research Clinical Department Phone/Fax: +7 (499) 268-50-10; +7 (495) 964-86-37
10, Stronymka St., Moscow, 107014
S. E. BORISOV
Moscow Municipal Scientific Practical Center of Tuberculosis Control
Russian Federation
Russian Federation
Deputy Director for Research and Clinical Activities Phone/Fax: +7 (499) 268-50-10; +7 (495) 964-86-37
10, Stronymka St., Moscow, 107014
References
1. Edict no. 109 by RF MoH as of 21.03.2003 On Improvement of TB Control Measures in the Russian Federation. Moscow, MAI Publ., 2003, 347 p.
2. Edict no. 951 by RF MoH as of 29.12.2014 On Approval of Guidelines for Improvement of Respiratory Tuberculosis Diagnostics and Treatment. [GARANT. RU] – URL: http://www.garant.ru/products/ipo/prime/doc/70749840/ (Accesses as of 07.07.2017.)
3. Chichevatov D.A. The model of scores for predicting binary variables in medical studies. Vestn. Sankt-Peterburgskogo Universiteta, 2007, no. 4, pp. 110-117. (In Russ.)
4. Agal S., Baijal R., Pramanik S. et al. Monitoring and management of antituberculosis drug induced hepatotoxicity. J. Gastroenterol. Hepatol., 2005, vol. 20, pp. 1745-1752.
5. Aithal G.P., Watkins P.B., Andrade R.J. et al. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther., 2011, no. 89, pp. 806-815.
6. Ambreen K., Sharma R., Singh K.P., Kumar S. Anti-tuberculosis drug-induced hepatotoxicity: a review. Int. J. Adv. Biotechnol. Res., 2014, vol. 5, no. 3, pp. 423-437.
7. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax, 1998, vol. 53, pp. 536-548.
8. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva, WHO; 2014. pp. 464.
9. Danan G., Benichou C. Causality assessment of adverse reactions to drugs: а novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol., 1993, no. 46, pp. 1323-1330.
10. Efron B., Tibshirani R.J. An introduction to the bootstrap. New York, Chapman& Hall, 1993, 435 p.
11. Fernández-Villar A., Sopeña B., Fernández-Villar J. et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int. J. Tuberc. Lung Dis., 2004, vol. 8, no. 12, pp. 1499-1505.
12. Glümer C., Carstensen B., Sandbaek A. et al. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care, 2004, vol. 27, no. 3, pp. 727-733.
13. Lee C.M., Lee S.S., Lee J.M. et al. Early monitoring for detection of antituberculous drug-induced hepatotoxicity. Korean J. Intern. Med., 2016, vol. 31, pp. 65-72.
14. Nagayama N., Masuda K., Baba M. et al. Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin. Kekkaku, 2003, vol. 78, no. 4, pp. 339-346.
15. Ramappa V., Aithal G. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J. Clin. Experimental Hepatology, 2012, vol. 3, no. 1, pp. 37-49.
16. Saukkonen J.J., Cohn D.L., Jasmer R.M. at al. An official ATS Statement: hepatotoxicity of antituberculosis therapy. Am. J. Respir. Crit. Care Med., 2006, vol. 174, pp. 935-952.
17. Singanayagam A., Sridhar S., Dhariwal J. et al. A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am. J. Resp. Crit. Care Med., 2012, vol. 185, pp. 653-659.
18. Vilariça A.S., Diogo N., André M., Pina J. Adverse reactions to antituberculosis drugs in in-hospital patients: severity and risk factors. Rev. Port. Pneumol., 2010, vol. 16, no. 3, pp. 431-451.
Review
For citations:
IVАNOVА D.A., BORISOV S.E. RISK ASSESSMENT AND MONITORING OF HEPATOTOXIC REACTIONS IN TUBERCULOSIS PATIENTS. Tuberculosis and Lung Diseases. 2017;95(9):40-48. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-9-40-48
Views:
976
Email this article 